The Neurotech Investing and Partnering Conference 2010

Boston, MA
Wednesday, May 19, 2010

Final Agenda            
Location:  Westin Waterfront Boston

 


Wednesday May 19, 2010

7:30 

Breakfast & Registration

8:30


Welcome: The Global Neurotech Industry 2010


Zack Lynch

Executive Director, Neurotechnology Industry Organization

9:00

Investing in Neurotech Panel

A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

Andrew Firlik
General Partner, Foundation Medical Partners

 

Stephen Knight
Managing Partner, Fidelity Biosciences

 

 

Art Pappas
Managing Partner, Pappas Ventures

 

 

Liam Ratcliffe
Venture Partner, New Leaf Venture Partners

 

 

Rajeev Shah
Senior Analyst, RA Capital

 

Moderator: Casey Lynch
Managing Director, NeuroInsights

10:00 

Networking and Refreshment Break

10:30


Novel Therapeutic Platforms in CNS

Companies present novel approaches for developing new therapeutics for the brain and nervous system including screening platforms, cell therapy approaches and neurodevice innovations.

 

Ulf Ljungberg
CEO, NeuroNova

 

 

Brad Margus
President & CEO, Envoy Therapeutics
 

 

 

Will Rosellini
CEO, MicroTransponder Inc.

 

 

Jim Schoeneck
President & CEO, BrainCells, Inc.

 

 

Session Chair: Ellen Baron
Partner, Oxford Bioscience Partners

 

 

 

 

11:30

Navigating Clinical Trials in Neurology and Psychiatry - Panel

Intelligent clinical trial design is critical to the success of any neurotech venture. The moderator will lead an insider panel in a discussion of specific tactics for improving the design and finding the fastest route to approval. Case studies will demonstrate lessons learned in Alzheimer's, depression, pain and more.

Mike Detke
Chief Medical Officer, MedAvante

 

Paul Wicks
Director, Research and Development, PatientsLikeMe

 

 

Remy Luthringer
CEO, Forenap Pharma

 

 

Suzan Onel
Partner, K&L Gates

 

Moderator: Joyce Cramer
President, Epilepsy Therapy Project

 

 

 

12:15

Lunch

1:45

Alzheimer's and Cognitive Disorders

 

As the population ages, the market for Alzheimer's and cognitive disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?

 

 

 

Greg Stock
CEO, Signum Biosciences

 

Konrad Glund
CEO, Probiodrug

 

Michael Pierschbacher
CEO, American Life Science Pharmaceuticals

 

Shawn Lyndon
CEO, Orasi Medical

 

 

Session Chair: Dan O'Connell
Managing Partner, NeuroVentures Capital

 

2:45

Neuroscience Research & Development Partnerships

What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations?

 

Chris Fibiger
Chief Scientific Officer, Biovail

 

Marianne De Backer
VP Business Development, Johnson & Johnson

 

Guy Seabrook
Sr. Director, Neuroscience Global External Research & Development, Eli Lilly

 

 

Emer Leahy
President and CEO, Psychogenics

 

 

Moderator: Ravi Kiron
Managing Director, Adjuvant Global Advisors

 

 

 

 

3:45

Networking and Refreshment Break

4:15


New Business Models in Neurotechnology

With venture capital steering away from long term and risky investments, neurosoftware, neurofeedback, neuromarketing and other new business models represent far lower risk and faster times to market.  What winning strategies are emerging in brain fitness, disease management, neuroplasticity, advertising and even sports performance?

 

Christopher deCharms
CEO, Omneuron

 

Alex Doman
CEO, Advanced Brain Technologies

 

Tom Dusenberry
CEO, Dusenberry Entertainment

 

 

Revere Greist
Founder, Waypoint Health Innovations

 

 

A.K. Pradeep
CEO, NeuroFocus

 

Session Chair: Roger Quy
General Partner, Technology Partners

 

 

 

5:30

Networking Reception

 

 


7:30


Continental Breakfast & Registration

8:30

Partnering and Licensing in Neurotech Panel

Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and partnering? Is there a new model for partnerships emerging? Is Big pharma looking to earlier stage product candidates for partnering and in-licensing? Can major medical device companies continue with their high rate of acquisitions?

 

Shafique Virani
Director CNS Business Development, Roche

 

 

 

Lothar Krinke
SVP, Research and Development, Medtronic

 

 

 

Leslie Coney
Sr. Director of Business Development, Biogen Idec

 

 

 

Reid Leonard
Executive Director, Licensing and External Research, Merck

 

 

 

David Schultz
Senior Director, Worldwide Business Development, Pfizer

 

 

 

Moderator: Christine de Los Reyes
Managing Partner, Biotech Partnering Solutions

 

 

 

 

 

 

 9:30

Frontiers in Neurotechnology

 

Novel neurotechnologies are being developed for new markets including sensory disorders, hypertension, obesity, sleep apnea, neuroimmunology and many others.  In this session we will hear from several companies on the cutting edge.

 

Jim Broderick
President, SetPoint Medical

 

 

Ed Boyden
Assistant Professor, MIT Media Lab

 

 

Ben Matteo
CEO, Eos Neuroscience

 

 

Marcelo Lima
President and CEO, ImThera Medical
 

 

 

Session Chair: Amy Belt
Vice President, Advanced Technology Ventures

 

 

 

 

10:30

Networking and Refreshment Break

11:00

Next Generation Psychiatry

Schizophrenia, anxiety, depression, and other psychiatric illnesses represent a large portion of the neurotech market. What are the most promising next generation treatments? How will devices change the treatment landscape?

 

Derek Small
COO & Acting CEO, Naurex

 

 

Bob Linke
President & CEO, Embera NeuroTherapeutics

 

 

Andreas Neef
Fellow, Bernstein Focus Neurotechnology

 

 

Walter Greenleaf
President & CEO, InWorld Solutions

 

 

Session Chair: Manuel Lopez-Figueroa
Vice President, Bay City Capital

 

 

 

 

12:00

Partnering Lunch sponsored by The Neurotechnology Industry Organization

 

 

 

1:00

Transitioning Neurotechnology Innovations to National Security Applications

The DoD and other national security agencies invested approximately $500M into neurotechnology research in 2009.  Brain science is growing in importance to national security, including for performance, well-being and treatment of soldiers.  Panelists will include program managers from national security agencies currently investing in neurotechnology who will outline current and future needs, as well as funding opportunities.

 


Amy Kruse

Executive Director, Neuroscience Division, Total Immersion Software

 

 

Kaleb McDowell
Soldier Performance Division, Neuroscience Strategic Research Initiative
Cognition & Neuroergonomics - Collaborative Alliance Manager, Army Research Laboratory

 

 

Dylan Schmorrow
Office of the Secretary of Defense, Assistant Director, Human Systems

 

 

Roy Stripling
Head Human Performance Training & Education, Office of Naval Research

 

 

Session Chair: Chris Forsythe
Distinguished Member of Technical Staff, Sandia National Laboratories

 

 

 

 

2:00

Emerging Treatments in Epilepsy and Pain

Drugs and devices with novel mechanisms of action are on the horizon to decrease

side effects and improve efficacy in treatment resistant populations for epilepsy and neuropathic pain.


Ronald Burch
CEO, Cerephex

Stephen Collins
President and CEO, NeuroTherapeutics Pharma

 

Bruce McCarthy
CEO, Afferent Pharmaceuticals

 

 

Linda Watkins
Founder, Xalud Therapeutics

 

Session Chair: Heath Lukatch
Partner, Novo Ventures

3:00

Networking and Refreshment Break

3:30

Translational Partnering and Investing Opportunities

This session will feature selected cutting edge, research projects from academia, research institutes and government labs ready for collaboration or hand off to industry. Don’t miss this showcase of the next generation of drugs, devices, and diagnostics selected from the top translational neuroscience projects. Supported in part by a grant from NINDS, NIA and NIMH.

 

 
Bruce Bean, Harvard
Permanently Charged Ion Channel Blockers for Neurogenic Inflammation

 

 

Gabriela Chiosis, Sloan Kettering Cancer Center
Small Molecule HSP90 Inhibitors for Alzheimer's Disease

 

 

Miles Cunningham, McLean Hospital
A New Generation of Neurosurgical Instrumentation for Crossing the Blood Brain Barrier

 

 

Hagit Eldar-Finkelman, Tel Aviv University
Potential Therapy Based on Substrate Competitive Inhibitors of GSK3

 

 

Ana Lukic, Predictek
Optimizing Data Analysis for Neuroimaging

 

 

Mike Vitek, Cognosci
ApoE-based Therapy for Alzheimer's Disease and Neurodegenerative Disorders

 

 

Junying Yuan, Harvard
Autophagy Modulation for Treatment of Neurodegenerative Disease

 

 

Session Chair: Jill Heemskerk
Program Director, Office of Translational Research, NINDS/ NIH

 

5:00

Conference Concludes

 

 

Contact Information